218600-48-7Relevant articles and documents
Novel heterocyclic ring-fused oleanolic acid derivatives as osteoclast inhibitors for osteoporosis
Wu, Jing,Bao, Bei-Hua,Shen, Qi,Zhang, Yu-Chao,Jiang, Qing,Li, Jian-Xin
supporting information, p. 371 - 377 (2016/03/01)
Osteoporosis is a major public health problem in our aging society. In the present study, a series of novel oleanolic acid (OA) derivatives were synthesized via modifications in the A-ring and C-28 position of OA, and their anti-bone resorption activities
Synthesis and biological evaluation of heterocyclic ring-substituted maslinic acid derivatives as novel inhibitors of protein tyrosine phosphatase 1B
Qiu, Wen-Wei,Shen, Qiang,Yang, Fan,Wang, Bo,Zou, Hui,Li, Jing-Ya,Li, Jia,Tang, Jie
scheme or table, p. 6618 - 6622 (2010/06/12)
A series of maslinic acid derivatives have been synthesized by introducing various fused heterocyclic rings at C-2 and C-3 positions. Their inhibitory effects on PTP1B, TCPTP and related PTPs are evaluated. Most of the compounds exhibited a dramatic increase in inhibitory potency and selectivity, the two most potent PTP1B inhibitors 20 (IC50 = 0.61 μM) and 29 (IC50 = 0.64 μM) showed about 10-fold more potent than lead compound maslinic acid. More importantly, 29 possesses the best selectivity of 6.9-fold for PTP1B over TCPTP.
Design and synthesis of 2-cyano-3,12-dioxoolean-1,9-dien-28-oic acid, a novel and highly active inhibitor of nitric oxide production in mouse macrophages
Honda, Tadashi,Rounds, BarbieAnn V.,Gribble, Gordon W.,Suh, Nanjoo,Wang, Yongping,Sporn, Michael B.
, p. 2711 - 2714 (2007/10/03)
New derivatives with electron-withdrawing substituents at the C-2 position of 3-oxoolean-1-en-28-oic acid were synthesized. Among them, 2- cyano-3,12-dioxoleam-1,9-dien-28-oic acid (CDDO) was 400 times more potent than previous compounds we have made as an inhibitor of production of nitric oxide induced by interferon γ in mouse macrophages (IC50, 0.4 nM). The potency of CDDO was similar to that of dexamethasone, although CDDO does not act through the glucocorticoid receptor.